FLUPENTHIXOL DECANOATE IN METHAMPHETAMINE SMOKING

甲基苯丙胺注射或吸烟（“冰”）越来越多地引起 严重的兴奋剂依赖，难以获得 药物和门诊心理治疗。 处于打开 试点试验，我们评估了一个仓库吨的功效，需要 不频繁IM给药，氟哌噻吨癸酸酯，用于 戒断吸烟非常相似的兴奋剂，可卡因。 十差 预后，门诊“快克”可卡因吸烟者给予 氟哌噻吨癸酸酯在一项开放标签，开放式试验。 氟哌 癸酸盐耐受性良好，并且似乎显著且迅速地 减少渴望和使用，比之前的治疗增加260% 在这些受试者的平均治疗时间中。 这 该申请提出了双盲氟哌噻吨癸酸酯试验， 与目前用于兴奋剂滥用的口服药物疗法相比， 地昔帕明 九十名滥用冰毒者将在一个 比较三种对照药物的随机治疗临床试验 在常规心理治疗基础上增加药物治疗：（a） 安慰剂地昔帕明+安慰剂I.M.癸酸氟哌噻吨（n=30）（B） 地昔帕明+安慰剂I.M.癸酸氟哌噻吨（n=30）（c）安慰剂 地昔帕明+肌内注射癸酸氟哌噻吨（n=30）。 结局评估 将是全面和多层面的。

Methamphetamine injection or smoking ("ice") is increasingly causing severe stimulant dependence that is refractory to available pharmacological and outpatient psychotherapeutic treatments. In an open pilot trial, we evaluated the efficacy of a depot xanthene requiring infrequent IM administration, flupenthixol decanoate, for efficacy in withdrawal from smoking the very similar stimulant, cocaine. Ten poor prognosis, outpatient "crack" cocaine smokers were administered flupenthixol decanoate in an open-label, open-ended trial. Flupenthixol decanoate was well tolerated, and appeared to markedly and rapidly decrease craving and use, producing a 260% increase over prior treatment in these subjects in their average time retained in treatment. This application proposes a double-blind flupenthixol decanoate trial with a comparison to a current oral pharmacotherapy for stimulant abuse, desipramine. Ninety methamphetamine abusers will be treated in a clinical trial with randomized treatment comparing three contrasting pharmacological treatments added to conventional psychotherapy: (a) Placebo Desipramine plus Placebo I.M. Flupenthixol Decanoate (n=30) (b) Desipramine plus Placebo I.M. Flupenthixol Decanoate (n=30) (c) Placebo Desipramine plus I.M. Flupenthixol Decanoate (n=30). Outcome assessments will be comprehensive and multidimensional.